This company has been marked as potentially delisted and may not be actively trading. Chromocell Therapeutics (CHRO) News Today Add Compare Share Share Headlines Stock AnalysisHeadlinesInsider TradesShort InterestTrendsBuy This Stock CHRO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private PlacementJune 27, 2025 | globenewswire.comChannel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing RulesMay 1, 2025 | globenewswire.comLigand subsidiaries, Chromocell Therapeutics to mergeApril 17, 2025 | markets.businessinsider.comChannel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on SuzetrigineDecember 20, 2024 | globenewswire.comChannel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block ModelDecember 18, 2024 | globenewswire.comChromocell Therapeutics Corp (CHRO)December 13, 2024 | investing.comChannel Therapeutics Corporation (CHRO)December 5, 2024 | finance.yahoo.comChromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program UpdatesNovember 23, 2024 | stockhouse.comChromocell Therapeutics Rebrands to Focus on Pain TreatmentsNovember 22, 2024 | markets.businessinsider.comChromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program UpdatesNovember 21, 2024 | markets.businessinsider.comChromocell Announces Name Change to “Channel Therapeutics Corporation†and Provides Therapeutic Program UpdatesNovember 21, 2024 | globenewswire.comChromocell Therapeutics Merges into Channel TherapeuticsNovember 20, 2024 | markets.businessinsider.comChromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical PainOctober 29, 2024 | globenewswire.comChromocell Announces Amendment to Stock Repurchase PlanOctober 24, 2024 | globenewswire.comChromocell to Participate in Life Sciences Investor Forum September 19thSeptember 16, 2024 | globenewswire.comChromocell Announces Stock Repurchase PlanAugust 7, 2024 | globenewswire.comChromocell to Participate in the Virtual Investor Lunch Break SeriesJuly 15, 2024 | globenewswire.comCHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024May 20, 2024 | investorplace.comChromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024May 13, 2024 | globenewswire.comChromocell Issues Letter to Stockholders from Chief Executive OfficerApril 9, 2024 | globenewswire.comChromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon ChandlerMarch 21, 2024 | globenewswire.comChromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023March 18, 2024 | globenewswire.comChromocell to Present at Sidoti Virtual Investor Conference March 13-14March 11, 2024 | globenewswire.comBenuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare SolutionsFebruary 27, 2024 | globenewswire.comChromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 MillionFebruary 21, 2024 | globenewswire.comChromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public OfferingFebruary 16, 2024 | globenewswire.com Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CHRO Media Mentions By Week CHRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CHRO News Sentiment▼0.000.77▲Average Medical News Sentiment CHRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CHRO Articles This Week▼00▲CHRO Articles Average Week Get the Latest News and Ratings for CHRO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Chromocell Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ImageneBio News Today PyroGenesis Canada News Today Akari Therapeutics News Today SCYNEXIS News Today Iterum Therapeutics News Today Leap Therapeutics News Today Dare Bioscience News Today Promis Neurosciences News Today Kezar Life Sciences News Today Enlivex Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CHRO) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
